Chanca Piedra and Fatty Liver Disease: What the Trials Found

Chanca piedra has a long reputation as a liver herb. In fatty liver disease, the human evidence behind that reputation is three small randomized trials, and each one used a different plant material: a standardized Phyllanthus niruri extract, Phyllanthus urinaria, and a capsule that combined Phyllanthus niruri with milk thistle. Neither of the two trials that reported liver fat found a difference from placebo. None of the three found a difference between groups in liver enzymes. One found that a fibrosis score fell on the extract and not on placebo.

Most of the remaining evidence comes from rats, mice and cells. Those studies report less liver fat in animals fed a high-fat or deficient diet, and they are kept in their own section below, after the human results. The page ends with the safety findings, the drug-enzyme findings, the approved treatments and what is still not known.


Table of Contents

  1. Fatty Liver Disease Has a New Name
  2. Chanca Piedra Covers More Than One Species
  3. The Three Human Trials at a Glance
  4. The One-Year Phyllanthus niruri Trial
  5. The Phyllanthus urinaria Biopsy Trial
  6. The Phyllanthus niruri and Milk Thistle Combination Trial
  7. A Related Trial in Alcoholic Hepatitis
  8. Pooled Analyses Cover Hepatitis B, Not Fatty Liver
  9. Animal and Cell Studies on Liver Fat
  10. Safety Findings
  11. Drug-Enzyme Interaction Findings
  12. Approved Treatments and Their Trials
  13. What Is Not Known
  14. Key Research Papers
  15. Connections
  16. Featured Videos

Fatty Liver Disease Has a New Name

In 2023 a multisociety Delphi consensus, led by three large pan-national liver associations, chose metabolic dysfunction-associated steatotic liver disease (MASLD) as the name to replace nonalcoholic fatty liver disease (NAFLD). A total of 236 panelists from 56 countries took part. Seventy-four percent of respondents felt the old nomenclature was "sufficiently flawed to consider a name change", and the terms "nonalcoholic" and "fatty" were felt to be stigmatising by 61% and 66% of respondents. The new definition requires at least 1 of 5 cardiometabolic risk factors. People who meet it and also drink more alcohol per week (140-350 g/wk for females and 210-420 g/wk for males) fall into a separate category, metabolic and alcohol related/associated liver disease (PMID 37363821).

The same process replaced nonalcoholic steatohepatitis (NASH), the inflamed form of the disease, with metabolic dysfunction-associated steatohepatitis (MASH) (PMID 41231713). The chanca piedra trials below were written under the older names, so each is reported here in the words it used.

The condition is common. A 2023 systematic review of 92 studies (N=9,361,716) put its global prevalence over 1990–2019 at 30.05%, rising from 25.26% in 1990–2006 to 38.00% in 2016–2019 (PMID 36626630). A 2025 consensus report of the American Diabetes Association states that liver steatosis affects approximately two out of three people with type 2 diabetes and raises their risk of steatohepatitis, cirrhosis, liver cancer and liver-related death (PMID 40434108). The disease itself is covered in depth on the fatty liver disease page.

Chanca Piedra Covers More Than One Species

Chanca piedra is the common name for Phyllanthus niruri, a small annual herb found throughout the tropical and subtropical regions of both hemispheres. A 2017 review of the plant listed the taxonomic inconsistency of Phyllanthus niruri among the gaps in earlier studies (PMID 28512988). Close relatives, among them Phyllanthus amarus and Phyllanthus urinaria, are studied for the liver under overlapping names; a 2025 review of the genus covered many species traded in India as "Bhumyamalaki" (PMID 38642916), and a 1985 paper gives "Bhumyamlaki" as a Sanskrit name for Phyllanthus niruri itself (PMID 22557474).

The species matters for reading the research. A study of Phyllanthus amarus notes that many past studies and clinical trials of the plant gave contentious results, which its authors say accentuates the need to standardize extracts (PMID 25755316). The 2011 Cochrane review of the hepatitis B trials called for future trials to report the species used (PMID 21491412). This page names the species in every study, because a result for one species is not a result for another.

Phyllanthus emblica, the fruit known as Indian gooseberry or amla, belongs to the same genus (PMID 34480995). It is a different plant from chanca piedra, and its studies are left out of this page. The species comparison page sets the three main species side by side.

The Three Human Trials at a Glance

Every figure is copied from the trial's abstract; nothing is pooled or converted.
TrialPlant material and amountPeople and lengthMain result
Abu Hassan et al., 2023 Standardized Phyllanthus niruri extract; the trial gave 3,000 mg daily Adults with mild-to-moderate nonalcoholic fatty liver disease; 112 on the extract, 114 on placebo; 12 months No difference in liver fat score or liver enzymes; fibrosis score fell on the extract (p = 0.001)
Wong et al., 2013 Phyllanthus urinaria; the abstract does not state the amount 60 patients with biopsy-proven nonalcoholic steatohepatitis; 40 on Phyllanthus, 20 on placebo; 24 weeks Not superior to placebo on the biopsy activity score (P = 0.24)
Shaker et al., 2025 Capsule of 200 mg Phyllanthus niruri extract plus 100 mg milk thistle extract; the trial gave one or two capsules 146 patients with an apparent risk factor for nonalcoholic steatohepatitis; three arms; 36 weeks Liver enzymes fell within the dose groups, with no difference between the three groups in percent change

The One-Year Phyllanthus niruri Trial

This was a 12-month randomized, double-blind, placebo-controlled trial in adults with mild-to-moderate nonalcoholic fatty liver disease. To enter, people needed a controlled attenuation parameter (CAP) score above 250 dB/m and a fibrosis score below 10 kPa. The trial gave a standardized Phyllanthus niruri extract at 3,000 mg daily (n = 112) or a placebo (n = 114). The main outcomes were the changes in the controlled attenuation parameter score and in liver enzymes, and the analysis was by intention to treat (PMID 37313177).

The authors concluded that the extract did not significantly reduce the controlled attenuation parameter score or liver enzyme levels, that the fibrosis score improved, and that further research is needed to determine its clinical benefits at different dosages.

The Phyllanthus urinaria Biopsy Trial

This was a placebo-controlled, parallel-group, double-blind randomized trial in 60 patients with histology-proven nonalcoholic steatohepatitis, meaning the diagnosis was made from a liver biopsy. Forty received Phyllanthus urinaria and 20 received placebo for 24 weeks. The abstract does not state the amount given. The authors tested the herb because it ameliorates steatohepatitis in animal studies. The main outcome was the change in the biopsy-based nonalcoholic fatty liver disease activity score (PMID 23034128).

The authors' conclusion: Phyllanthus is not superior to placebo in improving the activity score in patients with nonalcoholic steatohepatitis. This is the only trial of the three that judged the liver by biopsy.

The Phyllanthus niruri and Milk Thistle Combination Trial

This phase II, randomized, double-blind, placebo-controlled, three-arm trial tested a combined product of Phyllanthus niruri and milk thistle (Silybum marianum) extracts. Each capsule held 200 mg of a powdered extract from the aerial parts of Phyllanthus niruri and 100 mg of a powdered extract from milk thistle fruits. The trial gave placebo, one capsule (low dose) or two capsules (high dose) to 146 patients with an apparent risk factor for nonalcoholic steatohepatitis, randomized 1:1:1, for 36 weeks (PMID 39789561).

The authors wrote that the liver-protective effect in patients at risk of steatohepatitis still needs further assessment with more accurate investigation tools, a larger sample size and/or higher doses. The trial was registered retrospectively. Because every capsule also held milk thistle, its results cannot be credited to chanca piedra alone; the milk thistle page covers that herb.

A Related Trial in Alcoholic Hepatitis

One more randomized trial of Phyllanthus niruri concerns a different liver disease. In a block-randomized, double-blind, placebo-controlled trial in mild-to-moderate alcoholic hepatitis, 454 patients were screened, 100 were recruited and 71 were analyzed over 4 weeks. Liver and kidney function tests failed to show significant improvement with the plant. Total antioxidant levels rose (P = 0.034) and the authors reported an appetite-stimulant effect (P = 0.03) (PMID 34975132). It was not a fatty-liver trial, and its result cannot be read as one.

Pooled Analyses Cover Hepatitis B, Not Fatty Liver

No pooled analysis of Phyllanthus in fatty liver disease is among the records behind this page. The pooled analyses that exist are of chronic hepatitis B, a viral disease, and they are given here only as context for how the plant has fared in liver trials generally. The full account is on the hepatitis B page.

A 2025 review of many Phyllanthus species concluded, from in vitro and in vivo studies, that they had considerable liver-protective potential (PMID 38642916). That conclusion rests on laboratory and animal work, which is the subject of the next section.

Animal and Cell Studies on Liver Fat

Every result in this section comes from animals or cells, not people.

Safety Findings

In the human trials

In animals

Supplement liver injury in general

A 2017 research symposium review reported that herbal and dietary supplements account for 20% of cases of liver toxicity in the United States based on research data. It named anabolic steroids, green tea extract and multi-ingredient nutritional supplements as the major implicated agents, and noted that in multi-ingredient products the responsible component is usually unknown or can only be suspected (PMID 27677775). The review's abstract does not name Phyllanthus. The full safety picture is on the chanca piedra safety page.

Drug-Enzyme Interaction Findings

The plant's effect on the liver enzymes that clear drugs is part of its safety picture. The findings below are from human liver tissue, human cells and rats, not from interaction studies in people.

Approved Treatments and Their Trials

When the Phyllanthus urinaria trial was published in 2013, its authors wrote that there was no approved drug treatment for nonalcoholic steatohepatitis (PMID 23034128). That has since changed.

Each of the three Phyllanthus trials compared the plant material with a placebo. None tested it against or alongside resmetirom or semaglutide. Decisions about medicines and supplements for the liver belong with a clinician.

What Is Not Known

Key Research Papers

  1. Abu Hassan MR, Hj Md Said R, Zainuddin Z, Omar H, Md Ali SM, Aris SA, et al. Effects of one-year supplementation with Phyllanthus niruri on fibrosis score and metabolic markers in patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. Heliyon. 2023;9(6):e16652. PubMed PMID: 37313177
  2. Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, et al. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: a randomized trial. J Gastroenterol Hepatol. 2013;28(1):57-62. PubMed PMID: 23034128
  3. Shaker MK, Hassany M, Eysa B, Adel A, Zidan A, Mohamed S. The activity of a herbal medicinal product of Phyllanthus niruri and Silybum marianum powdered extracts (Heptex®) in patients with apparent risk factors for nonalcoholic steatohepatitis: a phase II, multicentered, randomized, double-blind, placebo-controlled clinical trial. BMC Complement Med Ther. 2025;25(1):8. PubMed PMID: 39789561
  4. Sowjanya K, Girish C, Bammigatti C, Prasanna Lakshmi NC. Efficacy of Phyllanthus niruri on improving liver functions in patients with alcoholic hepatitis: A double-blind randomized controlled trial. Indian J Pharmacol. 2021;53(6):448-456. PubMed PMID: 34975132
  5. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78(6):1966-1986. PubMed PMID: 37363821
  6. Osta EG, Saenz F, Jaganathan S, Thomas C, Tsai E, Surabhi V, et al. Current Update on Nomenclature, Diagnosis, and Management of Metabolic Dysfunction-associated Steatotic Liver Disease: Radiologists' Perspective. Radiographics. 2025;45(12):e240221. PubMed PMID: 41231713
  7. Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335-1347. PubMed PMID: 36626630
  8. Cusi K, Abdelmalek MF, Apovian CM, Balapattabi K, Bannuru RR, Barb D, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in People With Diabetes: The Need for Screening and Early Intervention. A Consensus Report of the American Diabetes Association. Diabetes Care. 2025;48(7):1057-1082. PubMed PMID: 40434108
  9. Kaur N, Kaur B, Sirhindi G. Phytochemistry and Pharmacology of Phyllanthus niruri L.: A Review. Phytother Res. 2017;31(7):980-1004. PubMed PMID: 28512988
  10. Pratima H, Shiraguppi A, Joojagar P, Shah K, Cheeraladinni SS, Singh PS, et al. Phytochemical profile and hepatoprotective potentiality of Phyllanthus genus: a review. J Pharm Pharmacol. 2025;77(2):189-205. PubMed PMID: 38642916
  11. Umarani D, Devaki T, Govindaraju P, Shanmugasundaram KR. Ethanol induced metabolic alterations and the effect of phyllanthus niruri in their reversal. Anc Sci Life. 1985;4(3):174-80. PubMed PMID: 22557474
  12. Krithika R, Verma RJ, Shrivastav PS, Suguna L. Phyllanthin of Standardized Phyllanthus amarus Extract Attenuates Liver Oxidative Stress in Mice and Exerts Cytoprotective Activity on Human Hepatoma Cell Line. J Clin Exp Hepatol. 2011;1(2):57-67. PubMed PMID: 25755316
  13. Saini R, Sharma N, Oladeji OS, Sourirajan A, Dev K, Zengin G, et al. Traditional uses, bioactive composition, pharmacology, and toxicology of Phyllanthus emblica fruits: A comprehensive review. J Ethnopharmacol. 2022;282:114570. PubMed PMID: 34480995
  14. Liu J, Lin H, McIntosh H. Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review. J Viral Hepat. 2001;8(5):358-66. PubMed PMID: 11555193
  15. Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species for chronic hepatitis B virus infection. Cochrane Database Syst Rev. 2011;2011(4):CD008960. PubMed PMID: 21491412
  16. Xia Y, Luo H, Liu JP, Gluud C. Phyllanthus species versus antiviral drugs for chronic hepatitis B virus infection. Cochrane Database Syst Rev. 2013;2013(4):CD009004. PubMed PMID: 23633363
  17. Martin KW, Ernst E. Antiviral agents from plants and herbs: a systematic review. Antivir Ther. 2003;8(2):77-90. PubMed PMID: 12741619
  18. Al Zarzour RH, Ahmad M, Asmawi MZ, Kaur G, Saeed MAA, Al-Mansoub MA, et al. Phyllanthus Niruri Standardized Extract Alleviates the Progression of Non-Alcoholic Fatty Liver Disease and Decreases Atherosclerotic Risk in Sprague-Dawley Rats. Nutrients. 2017;9(7):766. PubMed PMID: 28718838
  19. Zarzour RHA, Alshawsh MA, Asif M, Al-Mansoub MA, Mohamed Z, Ahmad M, et al. Adipocytokine Regulation and Antiangiogenic Activity Underlie the Molecular Mechanisms of Therapeutic Effects of Phyllanthus niruri against Non-Alcoholic Fatty Liver Disease. Nutrients. 2018;10(8):1057. PubMed PMID: 30096951
  20. Khater SI, Hussein MMA, Abdel-Magied SS, Lotfy MM, Khamis T, Abdelaziz S, et al. Phyllanthus niruri niosomes ameliorate obesity-induced hepatic steatosis in rats via modulating MALAT1/miR-206/GLP-1R signaling and hepatic lipid metabolism. Biol Res. 2026;59(1):27. PubMed PMID: 42045980
  21. Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, et al. Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology. 2008;47(2):473-83. PubMed PMID: 18157836
  22. Latha P, Chaitanya D, Rukkumani R. Protective effect of Phyllanthus niruri on alcohol and heated sunflower oil induced hyperlipidemia in Wistar rats. Toxicol Mech Methods. 2010;20(8):498-503. PubMed PMID: 20843268
  23. Krithika R, Jyothilakshmi V, Prashantha K, Verma RJ. Mechanism of protective effect of phyllanthin against carbon tetrachloride-induced hepatotoxicity and experimental liver fibrosis in mice. Toxicol Mech Methods. 2015;25(9):708-17. PubMed PMID: 26337812
  24. Londhe JS, Devasagayam TP, Foo LY, Shastry P, Ghaskadbi SS. Geraniin and amariin, ellagitannins from Phyllanthus amarus, protect liver cells against ethanol induced cytotoxicity. Fitoterapia. 2012;83(8):1562-8. PubMed PMID: 22982332
  25. Cheng HS, Goh BH, Phang SCW, Amanullah MM, Ton SH, Palanisamy UD, et al. Pleiotropic ameliorative effects of ellagitannin geraniin against metabolic syndrome induced by high-fat diet in rats. Nutrition. 2020;79-80:110973. PubMed PMID: 32916379
  26. Iregui-Parra J, Rojas Ossa V, Arias Salazar CM, López Estupiñán AD, Díaz Varela D, Sinisterra Parra LM, et al. Phyllanthus niruri in the management of nephrolithiasis: A systematic review of the literature. Actas Urol Esp (Engl Ed). 2025;49(6):501791. PubMed PMID: 40480426
  27. Paula VG, Cruz LL, Sene LB, Gratão TB, Soares TS, Moraes-Souza RQ, et al. Maternal-fetal repercussions of Phyllanthus niruri L. treatment during rat pregnancy. J Ethnopharmacol. 2020;254:112728. PubMed PMID: 32145330
  28. Costa Alves MD, Pereira DE, Bidô RCA, de Andrade CMS, Rufino Freitas JC, Bertozzo CCMS, et al. Phyllanthus niruri L. Administration during pregnancy and breastfeeding: Maternal evaluation and effects on initial development and adult behavior of male rat offspring. Brain Res. 2025;1850:149402. PubMed PMID: 39694168
  29. Ilangkovan M, Jantan I, Bukhari SN. Phyllanthin from Phyllanthus amarus inhibits cellular and humoral immune responses in Balb/C mice. Phytomedicine. 2016;23(12):1441-1450. PubMed PMID: 27765364
  30. Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):363-373. PubMed PMID: 27677775
  31. Taesotikul T, Dumrongsakulchai W, Wattanachai N, Navinpipat V, Somanabandhu A, Tassaneeyakul W, et al. Inhibitory effects of Phyllanthus amarus and its major lignans on human microsomal cytochrome P450 activities: evidence for CYP3A4 mechanism-based inhibition. Drug Metab Pharmacokinet. 2011;26(2):154-61. PubMed PMID: 21178301
  32. Taesotikul T, Nakajima M, Tassaneeyakul W, Yokoi T. Effects of Phyllanthus amarus on the pharmacokinetics of midazolam and cytochrome P450 activities in rats. Xenobiotica. 2012;42(7):641-8. PubMed PMID: 22339466
  33. Husain I, Abdulrahman B, Dale OR, Katragunta K, Idrisi M, Gurley BJ, et al. Interaction of Phyllanthus amarus extract and its lignans with human xenobiotic receptors, drug metabolizing enzymes and drug transporters. J Ethnopharmacol. 2025;339:119142. PubMed PMID: 39571700
  34. Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, et al. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024;390(6):497-509. PubMed PMID: 38324483
  35. Bansal MB, Patton H, Morgan TR, Carr RM, Dranoff JA, Allen AM. Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance. Hepatology. 2026;83(5):1326-1340. PubMed PMID: 41201884
  36. Anyiam AF, Muhibi MA, Arinze-Anyiam OC, Obeagu EI. Enhancing the bioavailability of Phyllanthus amarus: implications for traditional and modern medicine in Africa. Ann Med Surg (Lond). 2025;87(9):5631-5636. PubMed PMID: 40901185

PubMed Topic Searches

  1. PubMed: Phyllanthus and fatty liver
  2. PubMed: Phyllanthus niruri and nonalcoholic fatty liver disease
  3. PubMed: Phyllanthus and steatohepatitis, randomized trials

Back to Table of Contents

Connections

Back to Table of Contents